Springer, one of the leading publishers in the fields of science, technology and medicine, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010. Hormonal cancers include two of the most deadly cancer subtypes, cancers of the breast and prostate. In addition to these cancers, Hormones & Cancer will include research articles covering other less-commonly occurring cancer subtypes, such as thyroid, gynecologic and pituitary cancer. The journal will help to bridge the gap between those working in the two often disconnected fields of endocrinology and cancer research.
Hormones & Cancer will be a true translational journal, including basic scientific, epidemiological and clinical research papers. Because of the inherent multidisciplinary nature of the field, it is anticipated that the journal's focus will be on all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment. Translational studies, especially those utilizing novel cancer agents selectively designed to exert their action at hormone target tissues, will also be welcomed.
Springer and The Endocrine Society have worked together to create a highly respected, international editorial board that includes many of the leaders in this interdisciplinary field. The editor-in-chief will be Jonathan Li of the Department of Pharmacology, Toxicology, and Therapeutics at Kansas University School of Medicine in Kansas City, Kansas. Board members include V. Craig Jordan, the first to discover the breast cancer prevention properties of tamoxifen, and Kate Horwitz, Distinguished Professor of Endocrinology, Metabolism, and Diabetes at the University of Colorado Denver, and Past President of The Endocrine Society.
"The timing of this journal's launch could not be better," said Kate Horwitz. "The disciplines of endocrinology and oncology have been artifi
'/>"/>
| Contact: Joan Robinson joan.robinson@springer.com 49-622-148-78130 Springer Source:Eurekalert |